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Abstract
Background: The development of new modulator possessing high efficacy, low toxicity and high selectivity is a
pivotal approach to overcome P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in cancer treatment. In
this study, we suggest a new molecular mechanism that TRAIL (tumor necrosis factor-related apoptosis-inducing
ligand) down-regulates P-glycoprotein (P-gp) through inhibition of DNA-PKcs/Akt/GSK-3b pathway and activation
of caspases and thereby sensitize MDR cells to MDR-related drugs.
Results: MDR variants, CEM/VLB10-2, CEM/VLB55-8 and CEM/VLB100 cells, with gradually increased levels of P-gp
derived from human lymphoblastic leukemia CEM cells, were gradually more susceptible to TRAIL-induced
apoptosis and cytotoxicity than parental CEM cells. The P-gp level of MDR variants was positively correlated with
the levels of DNA-PKcs, pAkt, pGSK-3b and c-Myc as well as DR5 and negatively correlated with the level of c-FLIPs.
Hypersensitivity of CEM/VLB100 cells to TRAIL was accompanied by the activation of mitochondrial apoptotic
pathway as well as the activation of initiator caspases. In addition, TRAIL-induced down-regulation of DNA-PKcs/
Akt/GSK-3b pathway and c-FLIP and up-regulation of cell surface expression of death receptors were associated
with the increased susceptibility to TRAIL of MDR cells. Moreover, TRAIL inhibited P-gp efflux function via caspase-
3-dependent degradation of P-gp as well as DNA-PKcs and subsequently sensitized MDR cells to MDR-related
drugs such as vinblastine and doxorubicin. We also found that suppression of DNA-PKcs by siRNA enhanced the
susceptibility of MDR cells to vincristine as well as TRAIL via down-regulation of c-FLIP and P-gp expression and
up-regulation of DR5.
Conclusion: This study showed for the first time that the MDR variant of CEM cells was hypersensitive to TRAIL
due to up-regulation of DR5 and concomitant down-regulation of c-FLIP, and degradation of P-gp and DNA-PKcs
by activation of caspase-3 might be important determinants of TRAIL-induced sensitization of MDR cells to MDR-
related drugs. Therefore, combination of TRAIL and chemotherapeutic drugs may be a good strategy for treatment
of cancer with multidrug resistance.
Background
Acquired resistance to chemotherapeutic agents remains
a major obstacle for the effective treatment of many
advanced and metastatic cancers. Several mechanisms
are thought to be involved in the development of
multidrug resistance (MDR), defined by simultaneous
cross-resistance to a variety of anticancer drugs that dif-
fer in their chemical structures, modes of action, and
molecular targets [1-3]. Emergence of MDR is often
associated with over-expression of the MDR1 gene pro-
duct, P-glycoprotein (P-gp) [4]. In certain cancers, such
as chronic or acute myeloid leukemia and breast cancer,
over-expression of MDR1 gene is a prognostic indicator
for clinical outcome and correlates with a poor response
* Correspondence: kcdshbw@pusan.ac.kr; ksh7738@pusan.ac.kr
1Department of Biochemistry, Pusan National University School of Medicine,
Yangsan 626-870, South Korea
Seo et al. Molecular Cancer 2010, 9:199
http://www.molecular-cancer.com/content/9/1/199
© 2010 Seo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.to chemotherapy [5-8]. Therefore, inhibition of P-gp
function or expression can reverse P-gp-mediated MDR
and improve the efficacy of chemotherapy [9].
Previously, we have reported that an increased expres-
sion of DNA-dependent protein kinase (DNA-PK) parti-
cipates in the development of MDR, and inhibition of
DNA-PK leads to increase of drug sensitivity in MDR
cells [10]. DNA-PK comprises a catalytic subunit (DNA-
PKcs) with a DNA- binding Ku70 and Ku80 heterodimer
acting as the regulatory element. It has been proposed
that DNA-PK is a molecular sensor for DNA damage
that enhances the signal via phosphorylation of many
downstream targets [11]. Recently, it has been demon-
strated that DNA-PKcs-catalyzed RNA Helicase A phos-
phorylation enhanced the transcription of the MDR1
gene through the CAAT-like element of the MDR1 gene
promoter and thus DNA-PKcs played an important role
in regulation of P-gp expression by MDR1 promoter
activation [12].
The phosphoinositide 3-kinase (PI3K)/Akt pathway is
also frequently implicated in tumorigenesis and che-
motherapeutic resistance [13]. Recent studies have
shown that there is a significant correlation between the
phosphorylated, activated Akt and P-gp expression, and
inhibition of the PI3K/Akt signaling pathway can reverse
P-gp-mediated MDR [14-16]. Akt phosphorylation on
Ser473 (S473) is required for activation of Akt, and a
major Akt S473 kinase activity was found to be DNA-
PK, a member of the PI3K-related kinase subfamily of
protein kinases [17]. DNA-PKcs has been shown to
colocalize with Akt and enhance Akt phosphorylation
[18]. One of the downstream targets of pro-survival Akt
is GSK-3b, which is inactivated by phosphorylation on
Ser9 by Akt. The inactivation of GSK-3b through Akt-
mediated phosphorylation leads to down-regulate its
pro-apoptotic activity and inhibit the induction of cell
death. Death receptor-induced extrinsic apoptotic sig-
naling is also modulated by GSK-3b activity [19].
Recently, it has been shown that the extrinsic death
receptor pathway represents a suitable target for cancer
treatment [20]. Since TNF-related apoptosis inducing
ligand (TRAIL) has been shown to induce apoptosis in
various tumor cells, but only rarely in non-transformed
cells, TRAIL is currently assessed in clinical trials [21].
The extrinsic apoptotic signaling cascade is a vital pro-
cess initiated by activation of death receptors, DR4/DR5.
Stimulation of these death receptors causes receptor tri-
merization, followed by recruitment of FADD (Fas asso-
ciated with death domain protein) and caspase-8 (or
caspase-10) to form the death-inducing signaling com-
plex (DISC). DISC formation promotes autoactivation of
caspase-8/10 and the subsequent activation of effector
caspases, primarily caspase-3, -6 and -7, which imple-
ment the cell death program. Cellular FLICE inhibitory
protein (c-FLIP) is expressed as long form (c-FLIPL) and
short form (c-FLIPS) and inhibits caspase-8 binding to
FADD and prevents DISC formation and apoptosis and
splice forms [22]. Elevated Akt activity up-regulates
c-FLIP and inhibits TRAIL-induced apoptosis in cancer
cells [23].
It has been reported that MDR cells over-expressing
P-gp are more susceptible to TRAIL than their drug-
sensitive counterparts through various mechanisms
such as a reduced expression of endogenous Akt [24]
or enhancement of TRAIL binding to DR5 by P-gp
[25]. However, the mechanism underlying the
increased susceptibility of MDR cells to TRAIL
mediated cell death was not understood well. Here, we
demonstrated that TRAIL sensitized MDR cells to
MDR-related drugs by inhibition of DNA-PKcs/Akt/
GSK-3b pathway, activation of caspases and subse-
quent down-regulation of P-gp.
Results
The high susceptibility of MDR cells to TRAIL is associated
with up-regulation of DR5 and down-regulation of c-FLIPs
in the cells
Many studies have focused on overcoming MDR
through modulation of P-gp function [4,26]. Since
TRAIL as a targeted cancer therapy preferentially kills
cancer versus normal cells [20], we compared the cyto-
toxic and apoptotic effects of TRAIL between CEM
human lymphoblastic leukemic cell line and its multi-
drug resistant (MDR) variants, including CEM/VLB10-2,
CEM/VLB55-8,a n dC E M / V L B 100 isolated from parental
CEM cells. In a model of CEM cells with gradually
increasing expression of multidrug-resistance 1 (MDR1)
gene, the higher expression level of MDR1 gene in
MDR variants, the higher cytotoxicity to TRAIL as
shown in MTT assay (Figure 1A) and flow cytometric
analysis of apoptosis (Figure 1B), demonstrating that the
MDR cells were more susceptible to TRAIL-induced cell
death than TRAIL-insensitive parental cells. Since
TRAIL acts through the TRAIL receptors (DR5 and
DR4) to induce apoptosis [20], we compared the mRNA
levels of DR5 and DR4 between CEM and its MDR var-
iants (Figure 1C). The level of DR5 but not DR4 in
MDR variants was significantly increased as compared
with that in CEM cells. This result suggests that an
increased level of DR5 in MDR cells plays an important
role in the sensitization of the cells to TRAIL. To
understand further the factors that contribute to the
sensitization of MDR cells to TRAIL, we determined the
expression of c-FLIPL/S, an important downstream regu-
lator of death receptor-mediated apoptosis [27], in MDR
variants. We found that the mRNA level of c-FLIPS,b u t
not c-FLIPL, was significantly decreased in MDR var-
iants as compared to that in CEM cells. Therefore, our
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was closely associated with up-regulation of DR5 and
down-regulation of c-FLIPs in the cells.
TRAIL-induced apoptosis in MDR cells is mediated
through caspase activation and mitochondrial pathway
We determined if the increased susceptibility to TRAIL-
induced apoptosis of CEM/VLB100 cells was accompa-
nied by activation of caspases and the mitochondrial
apoptotic pathway (Figure 2). Consistent with the more
sensitive response of CEM/VLB100 cells to TRAIL-
induced cell death, cleavage and activation of procas-
pase-8 and -10, which are initiator caspases linked to
receptor mediated apoptotic pathway, occurred remark-
ably in CEM/VLB100 cells as compared to CEM cells. In
case of caspase-9 that has been linked to the mitochon-
drial death pathway, treatment of CEM/VLB100 cells
with TRAIL resulted in significant induction of
Figure 1 High susceptibility of MDR cells to TRAIL and up-regulation of death receptor and down-regulation of c-FLIP in the cells. (A)
mRNA levels of mdr1 in CEM cells and its MDR variants, CEM/VLB10-2, CEM/VLB55-8 and CEM/VLB100 cells were determined by RT-PCR (insert). To
determine the growth inhibitory effect of TRAIL, CEM cells and its multidrug-riesistant variants were treated with graded single doses of TRAIL,
and the percentage of cell survival was determined after 5 days incubation using the MTT assay. (B) CEM cells and its MDR variants were treated
with or without TRAIL (10 ng/ml) for 24 h. Thereafter, the percentage of apoptotic cells in each cell population was determined by Annexin V
staining and flow cytometry. Each bar represents the mean ± S.D. of triplicate experiments. *p < 0.05, **p < 0.01, ***p < 0.005 versus TRAIL
untreated control cells. (C) mRNA levels of DR4/DR5 and c-FLIPL/S in CEM cells and its MDR variants were determined by RT-PCR analysis. b-Actin
(Actin) was used as a loading control.
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compared to CEM cells, which did not show proteolytic
cleavage of procaspase-9. Finally, procaspase-3, an
executioner caspase, and PARP, a hallmark of caspase
activation, were cleaved profoundly in CEM/VLB100
cells compared with CEM cells.
Meanwhile, we investigated whether the modulation of
Bcl-2 family proteins is involved in TRAIL-induced
apoptosis of MDR cells. Down-regulation of Bcl-2 and
up-regulation of Bax apparently occurred after treatment
with TRAIL in CEM/VLB100 cells but not in CEM cells
and these results were followed by TRAIL-induced trun-
cation of Bid in CEM/VLB100 cells but not in CEM
cells, consistent with activation status of procaspase-9 in
CEM/VLB100 cells and CEM cells after treatment with
TRAIL. Therefore, these data indicated that TRAIL-
induces apoptosis occurred in the MDR cells through
caspase-dependent mitochondrial pathway as well as
receptor-mediated apoptotic pathway.
The increased expression of DNA-PKcs is associated with
up-regulation of P-gp and c-Myc expression via Akt/GSK-
3b pathway in MDR cells
It has been reported DNA-PKcs regulates c-Myc stabi-
lity via phosphorylation of Akt on Ser473, which in turn
inactivates GSK-3b by the phosphorylation of GSK-3b
on Ser9, resulting in stabilization of c-Myc [28]. The c-
Myc is known to be involved in regulating expression of
P-gp, the product of MDR1 gene [29,30] and renders
cells sensitive to TRAIL-induced apoptosis [31]. Since
Figure 2 Sensitization of MDR cells to TRAIL is mediated through caspase-dependent mitochondrial apoptotic pathway. The cell lysates
obtained from CEM or CEM/VLB100 cells after exposure to graded doses of TRAIL (1~10 ng/ml) for 24 h were subjected to western blot analysis
to monitor levels of caspase-8, -10, -9 and -3, Bid, truncated Bid (tBid), Bax and Bcl-2. The levels of PARP and its cleavage fragment (CF) in TRAIL-
treated cells were also determined.
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development of MDR phenotype [10], we determined
the relationships among P-gp, c-Myc and DNA-PKcs/
Akt/GSK-3b molecules in MDR variants (Figure 3). We
found that the gradually increased level of P-gp in
CEM/VLB10-2, CEM/VLB55-8 and CEM/VLB100 cells was
well correlated with the level of c-Myc in the each MDR
variant. Therefore, we examined whether the basal levels
of DNA-PKcs, phosphorylated Akt (pAkt) and phos-
phorylated GSK-3b (pGSK-3b)i nM D Rv a r i a n t sw e r e
compared with those in parental CEM cells. The basal
level of DNA-PKcs was gradually higher in CEM/VLB10-
2, CEM/VLB55-8 and CEM/VLB100 cells than in CEM
cells, which was followed by gradual increase in pAkt
and pGSK-3b levels without change in total Akt (tAkt)
and GSK-3a/b levels. We also observed that the basal
level of DR5 but not DR4 in MDR variants was signifi-
cantly increased as compared with those in CEM cells.
These results suggested that the increased expression of
DNA-PKcs in MDR cells might lead to up-regulation of
P-gp and c-Myc expression via phosphorylation of Akt
and GSK-3b proteins.
TRAIL-induced down-regulation of DNA-PKcs/Akt/GSK-3b
pathway and c-FLIP and up-regulation of DR4/DR5 cell
surface expression are associated with the susceptibility
to TRAIL of MDR cells
Since our data showed that the level of DR5 was well
correlated with the activity of the DNA-PKcs/Akt/GSK-
3b pathway in MDR cells, we determined whether the
levels of DNA-PKcs, Akt as a downstream target of
DNA-PKcs, and GSK-3b, a downstream target of the
Akt pathway, are modulated after treatment of CEM
and CEM/VLB100 cells with TRAIL (Figure 4A). When
both CEM and CEM/VLB100 cells were treated with
TRAIL, the levels of DNA-PKcs, pAkt and pGSK-3b as
well as P-gp were significantly decreased in CEM/
VLB100 cells as compared with those of CEM cells in a
dose-dependent manner. The decrease of pAkt was not
followed by decrease of tAkt, but the decrease of pGSK-
3b seemed to be associated with decrease of total GSK-
3b. These results were followed by down-regulation of
Mcl-1, one of the anti-apoptotic Bcl-2 family, that plays
a key role in acquired TRAIL resistance [32]. These
results suggest that down-regulation of both P-gp and
DNA-PKcs/Akt/GSK-3b pathway by TRAIL might be
played an important role in death receptor-mediating
TRAIL-induced apoptosis in the P-gp over-expressing
MDR cells with high expression of c-Myc. Meanwhile,
treatment of CEM/VLB100 cells with TRAIL led to a sig-
nificant suppression of mRNA level of c-FLIPL and c-
FLIPS and an increase in surface expression of DR4 and
DR5 (Figure 4B). These results suggest that an increase
in cell surface expression of DR4/DR5 and down-regula-
tion of c-FLIP and DNA-PKcs/Akt/GSK-3b pathway by
TRAIL play an important role in death receptor-mediat-
ing TRAIL-induced apoptosis in the MDR cells.
TRAIL inhibited P-gp efflux function via degradation of
P-gp and potentiated the cytotoxicity of MDR-related
drug in MDR cells
Since P-gp cleavage is dependent on caspase-3 activity
following treatment with apoptosis inducers [33], we
hypothesized that TRAIL-induced caspase-3 activation
in CEM/VLB100 cells may lead to the degradation of
P-gp. When the MDR cells were treated with TRAIL,
the cleavage of P-gp was accompanied with induction of
proteolytic cleavage of procaspase-3 to the active forms.
In addition, the cleavage of DNA-PKcs and PARP, well
known endogenous substrates of caspase-3 [34,35], was
observed in TRAIL-treated CEM/VLB100 cells (Figure
5A, left). These results were followed by prevention of
Figure 3 Expression of p-gp in MDR cells is associated with the
enhanced expression of c-Myc and DR5 and activation of DNA-
PKcs/Akt/GSK-3b pathway. The protein levels of P-gp, c-Myc, DNA-
PKcs, pAkt, GSK-3b, phosphorylated Akt (pAkt) at Ser 473, total Akt
(tAkt), phosphorylated GSK-3b (pSK3b) at Ser9, total GSK-3a/b, DR4
and DR5 were determined by western analysis. Actin was used as a
loading control.
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Page 5 of 15Figure 4 TRAIL inhibited P-gp expression and DNA-PKcs/Akt/GSK-3b signaling pathway and up-regulation of death receptors and
down-regulation of c-FLIP in MDR cells. (A) Cell lysates obtained from CEM or CEM/VLB100 cells treated with indicated dose of TRAIL for 24 h
were subjected to western blot analysis to monitor levels of P-glycoprotein (P-gp), DNA-PKcs, pAkt (Ser473), tAkt, pGSK3b (Ser 9), GSK-3a and
-3b, Mcl-1. (B) CEM/VLB100 cells treated with TRAIL (10 ng/ml) for 24 h were incubated on ice in the presence of DR4- and DR5-specific
antibodies (1:500), and subsequently labeled with FITC-conjugated secondary antibody (1:1000). The fluorescence intensity was analyzed with
flow cytometry. The thin line indicates that the cells only incubated with Goat IgG2a that was used as a control isotype antibody; the thick line
indicates the specific labeling (left). The cells treated with or without TRAIL, and changed mRNA level of c-FLIPL/S was determined by RT-PCR
analysis (right).
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pretreatment with Z-DEVD-FMK, a caspase-3-specific
inhibitor (Figure 5A, right). Therefore, we determined
whether TRAIL inhibited P-gp efflux function of the
MDR cells, using a flow cytometric functional efflux
assay based on the extrusion of the fluorescent sub-
strate, rhodamine 123 (Figure 5B). P-gp functions opti-
mally near 37°C, but it is inactive at 4°C. When P-gp
expressing CEM/VLB100 cells are preloaded with
rhodamine 123 and incubated at 4°C, they retain the
dye and consequently have high fluorescence levels. But,
CEM/VLB100 cells incubated at 37°C more readily efflux
the dye and show reduced fluorescence. Treatment with
TRAIL significantly reduced rhodamine123 efflux and
thereby increased the accumulation of rhodamine123 in
CEM/VLB100 cells. When we performed this functional
assay also on CEM cells, which does not express P-gp,
t h e r ew e r en od i f f e r e n c e si nt h ef l u o r e s c e n c ei n t e n s i t y
Figure 5 TRAIL inhibited P-gp efflux function in MDR cells by P-gp cleavage via caspase-3 activation. (A) The cell lysates obtained from
CEM/VLB100 cells treated with or without TRAIL (10 ng/ml) for 3 ~ 9 h (left) and the cell lysates of the MDR cells treated with TRAIL (5 ng/ml) for
6 h or pretreated with 50 μM Z-DEVD-FMK, a specific caspase-3 inhibitor, for 3 h and then with TRAIL for 6 h (right) were subjected to western
blot analysis to monitor levels of P-gp, DNA-PKcs, caspase-3 and PARP and their its cleavage fragment (CF). (B) flow cytometric assay of P-gp
efflux activity in TRAIL-treated MDR cells was based on extrusion of the fluorescent P-gp substrate, rhodamine123 (Rho123). The efflux activity of
P-gp is highly temperature sensitive because functions optimally 37°C but is inactive at 4°C. Cell suspension from CEM and CEM/VLB100 cells
treated with or without 10 ng/ml TRAIL for 6 h was incubated with Rho 123 and further incubated at 37°C for 3 h (TREATED 37°C as TRAIL-
treated cells or CTRL37°C as TRAIL-untreated control) to allow P-gp-mediated drug efflux or on ice as control (CTRL 4°C).
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this result suggests that the inhibitory effect of TRAIL
on P-gp efflux function might be due to caspase-3-
dependent P-gp cleavage.
We next examined whether the cytotoxicity of the
MDR-related drugs such vinblastine (VLB) and doxoru-
bicin (DOX) could be enhanced by pretreatment of
TRAIL (Figure 6A). We found that the cytotoxicity of
VLB and DOX was significantly enhanced in CEM/
VLB100 cells by pre-treatment with low dose of TRAIL
(1 ng/ml). These results suggest that inactivation of
P-gp by TRAIL may be a cause of sensitization of CEM/
VLB100 cells to MDR-related drugs, and thus the use of
TRAIL in combination with MDR-related drug for
growth inhibition in MDR cells might be overcome the
drug resistance of the MDR cells. In addition, to reveal
the synergistic cytotoxic mechanisms of the combined
treatment of TRAIL with MDR-related drug against
MDR cells, we determined the change of activity of cas-
pase-3 and expression of P-gp, DNA-PKcs and PARP in
Figure 6 TRAIL enhanced the cytotoxicity of MDR-related drug in MDR cells by the down-regulation of DNA-PKcs and P-gp via
caspase-3 activation. (A) CEM/VLB100 cells were treated with graded single doses of doxorubicin (DOX) or vinblastine (VLB) after pretreatment
of low dose of TRAIL (1 ng/ml) for 6 h. The percentage of cell survival after combined treatment of TRAIL with MDR-related drug was
determined after 5 days incubation using the MTT assay. Each bar represents the mean ± S.D. of triplicate experiments. ***p < 0.005 versus TRAIL
alone treated cells at the same dose point. (B) The cell lysates obtained from CEM/VLB100 cells co-treated with TRAIL (1 ng/ml) and indicated
dose of DOX were subjected to western blot analysis to monitor levels of P-gp, DNA-PKcs, caspase-3, PARP, and actin as a loading control.
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MDR-related drug and TRAIL (Figure 6B). As expected,
the combined treatment with DOX and TRAIL was
more effective than either treatment alone to down-reg-
ulate P-gp and DNA-PKcs and to increase subsequent
PARP cleavage via caspase-3 activation in the MDR
cells. Therefore, these results suggest that TRAIL might
be effective for overcoming the MDR phenotype of can-
cer cells by combination with MDR-related drug.
Suppression of DNA-PKcs by siRNA enhanced the
susceptibility of MDR cells to MDR-related drug as well as
TRAIL via up-regulation of DR5 and down-regulation of c-
FLIP and P-gp expression
To determine the role of DNA-PKcs on the expression
of c-FLIPL/S and DR4/DR5, which are major determi-
nants of responsiveness to TRAIL, and MDR1,w e
silenced DNA-PKcs in CEM/VLB100 cells using small
interfering RNA (siRNA) and determined the changed
mRNA levels of the genes using RT-PCR analysis (Fig-
ure 7A). The apparent increase in the mRNA level of
DR5 was observed in the MDR cells after transfection
with DNA-PKcs siRNA compared with scrambled
siRNA, and DR4 also increased slightly. Conversely, the
mRNA level of c-FLIPS but not c-FLIPL in CEM/VLB100
cells was significantly reduced after transfection with
DNA-PKcs siRNA. We also found that siRNA-mediated
silencing of DNA-PKcs significantly down-regulated the
expression of MDR1 gene in the MDR cells. Moreover,
the increased transcription of DR5 gene was followed by
increased cell surface expression of DR5 in CEM/VLB100
cells after transfection with DNA-PKcs siRNA (Figure
7B). These results suggest that the down-regulated
DNA-PKcs after treatment with TRAIL may play impor-
tant roles in the regulation of death receptors and
c-FLIP as well as MDR1 gene expression, and the inhibi-
tion of DNA-PKcs in MDR cells may enhance the
susceptibility to TRAIL as well as MDR drugs via up-
regulation of DR5 and down-regulation of c-FLIP and
P-gp expression, respectively. In addition, we demon-
strated that the inhibition of DNA-PKcs by transfection
with DNA-PKcs siRNA caused the reduction of pAkt,
pGSK-3b a n dP - g pl e v e l si nC E M / V L B 100 cells (Figure
8A). The reduction of pAkt level was not followed by
the reduction of total Akt, while the reduction of pGSK-
3b level was associated with the reduction of total
Figure 7 Supprerssion of DNA-PKcs up-regulated surface expression of DR5 and down-regulated the expression of c-FLIPs. (A) CEM/
VLB100 cells were transfected with a siRNA against DNA-PKcs or scrambled siRNA as a control. After 48 h, the total RNA extracted from
transfectant of CEM/VLB100 cells performed RT-PCR analysis to monitor the mRNA levels of DNA-PKcs, DR4/5, c-FLIPL/S , MDR1, and actin as a
loading control. (B) The transfectant incubated with an anti-DR4 or -DR5 (1:500), and subsequently labeled with FITC-conjugated secondary
antibodies (1:1000) to determine the surface expression of DR4 and DR5. Goat IgG2a was also used as control isotype antibody.
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decrease in P-gp and c-FLIPs and a concurrent increase
in cleaved PARP, which was accelerated by TRAIL.
These results suggest that suppression of DNA-PKcs
would lead to increased susceptibility to TRAIL-induced
cytotoxicity in MDR cells. Therefore, we next examined
whether siRNA-mediated suppression of DNA-PKcs
affects the susceptibility of CEM/VLB100 cells to TRAIL-
induced cytotoxicity. After transfection with DNA-PKcs
siRNA or scrambled siRNA, the transfected cells were
treated with indicated doses of TRAIL for 5 days. The
susceptibility to TRAIL-induced cytotoxicity of CEM/
VLB100 cells was significantly increased after transfection
with DNA-PKcs siRNA (Figure 8B, left). Furthermore,
Figure 8 Potentiated suppression of DNA-PKcs expression by TRAIL leads to a severe inhibition of both Akt/GSK-3b phosphorylation
and P-gp and c-FLIPs expression and enhances the cytotoxicity of TRAIL and of MDR-related drug in MDR cells. (A) CEM/VLB100 cells
were transfected with a siRNA against DNA-PKcs or scrambled siRNA as a control. After 48 h, the transfectant was treated with or without TRAIL
(1- and 10 ng/ml for 24 h), and the changed level of DNA-PKcs, pAkt (Ser473), tAkt, pGSK3b (Ser9), GSK-3a/b, P-gp, PARP, c-FLIPL/S and actin was
performed by western blot analysis. (B) Each transfectant was treated with indicated doses of TRAIL or vincristine (VCR). After 5 days, the
percentage of growth inhibition was determined incubation using the MTT assay. Data represent means ± S.D. of triplicate experiments.
**p < 0.001, ***p < 0.005 versus cells transfected with scrambled siRNA at the same dose point.
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of DNA-PKcs affects the susceptibility of CEM/VLB100
cells to vincristine (VCR) (Figure 8B, right). These
results suggest that targeting of DNA-PKcs could
enhance the susceptibility of MDR-related drug as well
as TRAIL on P-gp over-expressing MDR cells with high
expression of DNA-PKcs.
Discussion
Although targeted drugs are being developed or used in
some leukemia, chemotherapeutic drugs are still useful
for the treatment of leukemia. However, acquired resis-
tance against MDR-related drugs is a serious problem in
the management of leukemic patients. Altered expres-
sion of various kinds of protein and enzymes could be
seen in MDR-type cancer cells [2,9]. In the present
study, we suggest a new molecular mechanism that
TRAIL down-regulates P-gp through inhibition of DNA-
PKcs/Akt/GSK-3b pathway and activation of caspases
and thereby sensitize MDR cells to MDR-related drugs.
TRAIL is emerging as most promising agent for can-
cer therapy, because it induces apoptosis in a variety of
cancers and transformed cells without any toxicity to
normal cells [20]. But, it has been reported that a major-
ity of human leukemic cells such as CEM, K562 and
Molt-4 cells are relatively resistant to TRAIL-induced
apoptosis [36,37]. In our study, interestingly, MDR var-
iants derived from human lymphoblastic leukemia CEM
cells showed a hypersensitive response to TRAIL com-
pared with parental CEM cells. MDR variants, CEM/
VLB10-2, CEM/VLB55-8 and CEM/VLB100 cells with gra-
dually increased levels of P-gp were gradually more sus-
ceptible to TRAIL-induced apoptosis and cytotoxicity
than CEM cells. This result was supported by the find-
ings that the expression of DR5 was gradually up-regu-
lated in the CEM/VLB10-2, CEM/VLB55-8 and CEM/
VLB100 cells, and conversely, the expression of c-FLIPs
was gradually down-regulated in the MDR variants as
compared with those of CEM cells. Therefore, modula-
tion of TRAIL receptor pathway including up-regulation
of DR5 and down-regulation of c-FLIPs might contri-
bute to TRAIL sensitization of MDR cells. It has been
reported that TRAIL responsiveness correlates with a
reduced expression of endogenous Akt in MDR-U2OS
human osteosarcoma cell line [24], and P-gp enhances
TRAIL-triggered apoptosis by interacting with the death
receptor DR5 in the MDR1-transfected MCF-7 breast
cancer cell line [25]. Therefore, it could be suggested
that a marked sensitivity to TRAIL of MDR cells might
be mediated by complex mechanisms, not a single
mechanism. In the present study, hypersensitivity to
TRAIL of CEM/VLB100 cells, MDR variant of CEM
cells, was accompanied by the activation of the mito-
chondrial apoptotic pathway by the cleavage of bid as
well as the activation of caspase-8 and -10, which are
apoptotic characteristics of the type II cells and caspase-
3 and -9 [38]. We also observed an increase in cell
surface expression of DR4/DR5 and down-regulation of
c-FLIP by TRAIL in MDR-variant of CEM cells. These
results suggest that there might be a positive feedback
regulation in TRAIL receptor signaling leading to inten-
sification of sensitivity to TRAIL in MDR-variant of
CEM cells.
Oncogene c-Myc is known to act as an important reg-
ulator for TRAIL sensitivity in cancer cells. It has been
shown that c-Myc induces and represses the transcrip-
tion of DR5 [39] and c-FLIP [40], respectively, therefore
enhancing the sensitivity of cancer cells to TRAIL-
induced apoptosis. Recently, it has been reported that
abnormal overexpression of DNA-PKcs may contribute
to cell proliferation and even oncogenic transformation
by stabilizing the c-Myc oncoprotein via at least the
Akt/GSK3 pathway [28]. Previously, we have demon-
strated that the increased expression of DNA-PKcs is
associated with the development of drug resistance in
MDR variants of CEM cells [10]. In addition, the c-Myc
is known to be involved in regulating expression of P-
gp, the product of MDR1 gene [29,30]. It has been
reported that elevated P-gp expression in MDR cells is
accompanied by increased level of pAkt [41]. Once
phosphorylated, activated Akt inactivate GSK-3b
through phosphorylation at Ser9, resulting in stabiliza-
tion and activation of b-catenin that enhanced P-gp
expression [42]. In the present study, the gradually
increased level of P-gp, was well correlated with the gra-
dually increased levels of c-Myc, DNA-PKcs, pAkt and
pGSK-3b in MDR variants, CEM/VLB10-2, CEM/VLB55-8
and CEM/VLB100 cells, suggesting that the molecular
changes are not dependent on the each subline type, but
implicate the causal relationships between the mole-
cules, which have been changed during the process of
MDR acquisition. And the increased level of DR5 and
decreased level of c-FLIPs in the MDR-variants of CEM
cells also might be associated with the up-regulated c-
Myc since it has been reported that c-Myc up-regulated
the DR5 receptor and down-regulated c-FLIP [39,40].
We also found that the expression of up-regulated
molecules in CEM/VLB100 cells including P-gp,
DNA-PKcs, pAkt and pGSK-3b were suppressed after
treatment with TRAIL. Akt and GSK-3b are signaling
molecules downstream to DNA-PKcs. We showed that
t h ep h o s p h o r y l a t e df o r mo fA k ta n dG S K - 3 b would be
decreased in TRAIL-treated CEM/VLB100 cells since
DNA-PKcs was down-regulated by TRAIL treatment.
Therefore, our data indicated that TRAIL caused the
down-regulation of P-gp in MDR cells by the inactiva-
tion of DNA-PKcs/Akt/GSK-3b pathway. Since
these molecules are related with drug-resistance,
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3b after treatment with TRAIL might lead to the hyper-
sensitivity to MDR-related drugs of MDR-variant of
CEM cells. Indeed, inhibition of Akt enhances suscept-
ibility to TRAIL by up-regulation of death receptors [43]
and down-regulation of c-FLIP [44] and down-regulates
P-gp expression in multidrug-resistant human T-acute
leukemia [14].
Our study also showed that anti-apoptotic Bcl-2 and
Mcl-1 proteins were over-expressed in CEM/VBL100
cells and the levels of these proteins and Bax were sig-
nificantly decreased and increased by Bcl-2 and Mcl-1,
the antiapoptotic Bcl-2 family proteins, were over-
expressed in CEM/VBL100 cells in comparison with
CEM cells, and the levels of these anti-apoptotic pro-
teins and Bax were significantly decreased and
increased by treatment of TRAIL in CEM/VBL100 cells,
respectively, suggesting that TRAIL-induced apoptosis
of MDR cells was mediated through mitochondria-
dependent pathway as well as caspase activation. Bcl-2
and Mcl-1 are often highly expressed in chemother-
apy-resistant cancers and prevents apoptosis by inacti-
vating pro-apoptotic Bax and Bak [45,46]. The
increased expression of Bcl-2 or Bcl-xL was the com-
mon feature of P-gp-related drug-resistant human leu-
kemic ce1l lines [47]. Over-expression of Mcl-1
decreased sensitivity of leukemia cells to cytotoxic che-
motherapeutic agents [45] and specific down-regula-
tion of Mcl-1 via RNA interference sensitized
multidrug-resistant leukemia cells towards chemother-
apy and induced apoptosis [48]. Therefore, the reduc-
tion of Bcl-2 and Mcl-1 after exposure to TRAIL may
be in part a cause of TRAIL-induced sensitization of
CEM/VLB100 cells to MDR-related drugs.
Moreover, our data showed the cleavage of P-gp and
DNA-PKcs by treatment with TRAIL. Recently, it has
been shown that the cleavage of P-gp (170 kDa) is
dependent on caspase-3 during apoptotic cell death
induced by LY294002, H2O2,a n dZ - L E H D - F M Ki n
MDR variant of CEM cells [33]. DNA-PKcs is also a
substrate of caspase-3 [35]. Here, we demonstrated that
the degradation of P-gp and DNA-PKcs during treat-
ment of CEM/VLB100 cells with TRAIL was a caspase-3
dependent manner. This result was followed by the sig-
nificant reduction of rhodamine123 efflux and the
increased sensitivity to MDR-related drugs such as VLB
and DOX after exposure to TRAIL in CEM/VLB100
cells, suggesting that the degradation of P-gp as well as
the down-regulation of Bcl-2 and Mcl-1 could be
involved in sensitization of MDR cells to MDR-related
drug after treatment with TRAIL. Since the expression
of DNA-PKcs regulates MDR1 gene [12] and cellular c-
Myc protein levels [28], which can affect TRAIL sensi-
tivity in cancer cells as described above, we showed that
knockdown of DNA-PKcs with specific siRNA led to the
increased expression of DR5 and the decreased expres-
sion of c-FLIP and caused the reduction of pAkt, pGSK-
3b a n dP - g pl e v e l si nC E M / V B L 100 cells. These results
resembled the effects of TRAIL on the CEM/VBL100
cells. Therefore, DNA-PKcs may play an important role
on TRAIL sensitivity in MDR-variant of CEM cells.
Conclusions
In conclusion, this study showed for the first time that
the MDR-variants of CEM cells with an increased P-gp
and c-Myc were hypersensitive to TRAIL and that the
degradation of both P-gp and DNA-PKcs after exposure
to TRAIL might be an important determinant of sus-
ceptibility to TRAIL-induced apoptosis in MDR cells. In
addition, the treatment with TRAIL caused severe
down-regulation of the up-regulated P-gp and DNA-
PKcs in MDR cells and consequently sensitized the
MDR cells to MDR-related drugs. Therefore, combina-
tion of TRAIL and chemotherapeutic drugs may be a
good strategy for treatment of cancer with multidrug
resistance, and DNA-PKcs/Akt/GSK-3b signaling path-
way may be an important target to overcome multidrug
resistance.
Methods
Cell culture and Reagents
Human lymphoblastic leukemia CCRF-CEM (CEM) line
and its the multidrug-resistant sublines, CEM/VLB10-2,
CEM/VLB55-8,a n dC E M / V L B 100 [10], were cultured in
RPMI 1640 medium supplemented with 10% fetal
bovine serum (FBS, GIBCO BRL, Life Technologies,
Inc.). The recombinant human soluble TRAIL was pur-
chased from R&D System (Minneapolis, MN). Vinblas-
tine, vincristine, doxorubicin and Rho123 were obtained
from Sigma-Aldrich (St. Louis, MO).
Cell Proliferation Assay
Cell proliferation was measured either by counting
viable cells by using the 3-(4, 5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT; Sigma Chemi-
cal Company, St. Louis, MO) colorimetric dye-reduction
method. Exponentially growing cells (5 × 10
3 cells/well)
were plated in 96 well and incubated in growth medium
treated with indicated condition of TRAIL and/or drug
at 37°C. After 5 days, the medium was aspirated using
centrifugation and MTT-formazan crystals solubilized in
100 μl DMSO. The optical density of each sample at
570 nm was measured using ELISA reader. The optical
density of the media was proportional to the number of
viable cells. Inhibition of proliferation was evaluated as a
percentage of control growth (no drug in the sample).
All experiments were repeated at least two experiments
in triplicate.
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CEM/VLB100 cells (2 × 10
6 cells) from the culture media
were spun down at 500 × g, washed with phosphate-
buffered saline (PBS) and resuspended in 500 μlP B S .
The cells were then incubated with 5 μlo fg o a tI g G 2 a ,
anti-DR4 or anti-DR5 polyclonal goat antibody (1:100,
R&D, Minneapolis, MN) for 1 h. After washing with
PBS, FITC-conjugated rabbit anti-goat polyclonal anti-
body (1:200, Sigma-Aldric hC o . ,S t .L o u i s ,M O )w a s
added to the cell suspension and incubated for 1 h on
ice. After rinsing with PBS, the samples were analyzed
with a FACSort flow cytometer (Becton Dickinson, San
Jose, CA). The data were analyzed using the CellQuest
program.
RT-PCR analysis
Total cellular RNA was isolated using RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol and the levels of RNA transcripts were
assessed with The Titan One Tube RT-PCR System (MJ
research Inc, NV, USA). One mg of total cellular RNA
was reverse transcribed using Maloney murine leukemia
virus reverse transcriptase (Invitrogen, Paisley, UK) with
each dNTP and 1 μg oligo dT. Amplification of 1 μlo f
these cDNA by PCR was performed using the following
gene-specific primers: DR4 (forward), 5’-CTGAG-
CAACGCAGACTCGCTGTCCAC-3’ and (reverse), 5’-
AAGGACACGGCAGAGCCT GTGCCAT-3’;D R 5( f o r -
ward), 5’-CTGAAAGGCATCTGCTCAGGTG-3’ and
(reverse), 5’-CA GAGTCTGCATTACCTTCTA G-3’;
FLIPL (forward), 5’-TTCCAGGCTTT CGGTTTCTT-3’
and (reverse), 5’-GTCCGAAACAAGGTGAGGGT-3’;
FLIPS (forward), 5’-ACCCTCACCTTG TTTCGGAC-3’
and (reverse), 5’-CTTTTGGATTGCTGCTTGGA-3’; b-
actin (forward), 5’-CAGAGCAAGAGAGGCATCCT-3’
and (reverse), 5’-TTGAAGGTCTC AAACATGAT-3.’
The resulting total cDNA was used in PCR performed
in total volume of 20 μl using Taq polymerase (Solgent
Co., Korea) at 94°C for denaturation for 60 sec, 60°C for
annealing for 60 sec, and 72°C for amplification for 90
sec for 30 cycles, followed by a final extension at 72°C
for 12 min. The amplified fragments were separated on
1.5% agarose gel and visualized with ethidium bromide
staining.
Western blot analysis
Protein samples were separated by SDS-PAGE and
blotted to nitrocellulose membrane (Hybond-ECL, GE
Healthcare). The membrane was incubated with antibody
as specified, followed by secondary antibody conjugated
with horseradish peroxidase. Specific antigen-antibody
complexes were detected by enhanced chemilumines-
cence (PerkinElmer, Life science). Western blot analysis
was performed with the following antibodies: anti-Bax,
anti-caspase-3, anti-PARP, anti-Bcl-2 (Santa Cruz Bio-
technology, CA), anti-Akt, anti-phospho-Akt (Ser 473),
anti-caspase-8, anti-caspase-9 (Cell signal, Danvers, MA),
anti-DNA-PKcs (Thermo Fisher Scientific, CA), anti-
DR5, anti-caspase-10 (Calbiochem, Germany), anti-
pGSK-3b (Ser8), anti-GSK-3b, anti-GSK-3a,a n t i - c - M y c
(Epitomics, CA), anti-DR4 (R&D Systems, MN) and anti
b-actin (Sigma-Aldrich) antibodies, Secondary antibodies
were obtained from GE Healthcare.
Preparation of siRNA Transfection
The siRNA used for targeted silencing of DNA-PKcs
were (5’-CAGUCUUAGUCCGGAUCAUdTdT-3’).
CEM/VLB100 cells were transfected with 0.1 uM siRNA
for 48 h by oligofectamine according to the manufac-
ture’s protocol (InVitrogen, Carlsbad, CA). In brief,
CEM/VLB100 (2 × 10
5 cells/well) were seeded of 6-well
plates and added to the siRNA/oligofectamine complex.
Cells were incubated for 4 h at 37°C in serum free
RPMI medium and then FBS was added. After 48 h, the
cells were treated with TRAIL for another 24 h and col-
lected for western blot analysis to determine the levels
of DNA-PKcs and other indicated proteins.
Apoptosis assay
Cells (2 × 10
5 cells/ml) were treated with or without
TRAIL and/or indicated drug for 24 h and the cells
were centrifuged and resuspended in 500 μl of the stain-
ing solution containing Annexin V fluorescein (FITC
Apoptosis detection kit; BD ParMingen San Diego, CA)
and propidium iodide in PBS. After incubation at room
temperature for 15 min, cells were analyzed by flow
cytometry. Annexin V binds to those cells that express
phosphatidyl serine on the outer layer of the cell mem-
brane, and propidium iodide stains the cellular DNA of
those cells that have a compromised cell membrane.
This allows for the discrimination of live cells (unstained
with either fluorochrome) from apoptotic cells (stained
only with Annexin V) and necrotic cells (stained with
both Annexin V and propidium iodide).
Flow-cytometric dye-efflux assay for multidrug resistance
The accumulation of rhodamine 123, a fluorescent sub-
strate of P-gp, in CEM and CEM/VLB100 cells treated
with or without TRAIL was measured using a FACS
flowcytometer (FACScalibur, BD Biosciences, San Jose,
CA) equipped with an ultraviolet argon laser (excitation
at 488 nm and emission at 530 ± 15 nm). Cell suspen-
sion (500 μl) from CEM and CEM/VLB100 cells treated
with or without 10 ng/ml TRAIL for 6 h was incubated
with rhodamine 123 (0.5 μg/ml) at 37°C for 30 min.
After incubation, the cells were washed with ice-cold
PBS and further incubated at 37°C for 3 h to allow P-
gp-mediated drug efflux or on ice (4°C) as control. Cells
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pended in PBS containing. Cellular fluorescence was
analyzed immediately by using Flow cytometer.
Statistical analysis
The results obtained were expressed as the mean ± S.E.
of at least three independent experiments. The statistical
significance of differences assessed using the Student’st -
test. *p < 0.05, **p < 0.01, ***p <0 . 0 0 5w a sc o n s i d e r e d
statistically significant in all experiments.
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